NCT00344032 - Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women | Biotech Hunter

Enrollment

354

Participants

Timeline

Start Date

July 28, 2006

Primary Completion Date

December 1, 2007

Study Completion Date

December 4, 2007

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

Placebo

Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

BIOLOGICAL

HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)

Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

Trial Locations (4)

GSK Investigational Site, New Delhi

GSK Investigational Site, Chandigarh

GSK Investigational Site, Kolkata

GSK Investigational Site, Mumbai